Renal cell carcinoma

Molecular features and treatment updates

Research output: Book/ReportBook

1 Citation (Scopus)

Abstract

This book provides a comprehensive review of diagnosis and treatments of renal cell carcinoma (RCC) for practitioners and researchers with an interest in this disease. A major aim of the book is to present the most important and most recent advances in molecular bases and targeted therapy for this neoplasm. The remarkable resistance to chemotherapy and radiotherapy and the minimum contribution of cancer genes that commonly mutate in other adult epithelial cancers have made RCC highly distinct from other types of solid neoplasms. In the past decade, however, treatment options for RCC have been expanding and moving quickly toward laboratory-based and molecular-targeted therapies. Advances in RCC therapy also have brought novel treatment options to other types of cancer, such as a TKI for hepatocellular carcinoma and gastrointestinal tumors, as well as mTOR inhibitors to progressive neuroendocrine tumors of pancreatic origin and to breast cancer, suggesting that RCC is no longer an "orphan disease" in the field of molecular oncology. Additional topics covered in the book include pharmacokinetics and pharmacodynamics in molecular-targeted agents and the putative mechanism of resistance to anti-angiogenic agents, such as intratumoral heterogeneity or cancer stem cell population. This volume provides the latest and most useful information for all readers who are eagerly devoted to curing renal cell carcinoma.

Original languageEnglish
PublisherSpringer Japan
Number of pages381
ISBN (Electronic)9784431555315
ISBN (Print)9784431555308
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Renal Cell Carcinoma
Tumors
Cells
Pharmacodynamics
Pharmacokinetics
Oncology
Chemotherapy
Radiotherapy
Stem cells
Molecular Targeted Therapy
Curing
Genes
Neoplasms
Therapeutics
Neuroendocrine Tumors
Neoplastic Stem Cells
Neoplasm Genes
Cell- and Tissue-Based Therapy
Rare Diseases
Hepatocellular Carcinoma

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Renal cell carcinoma : Molecular features and treatment updates. / Oya, Mototsugu.

Springer Japan, 2017. 381 p.

Research output: Book/ReportBook

@book{35d83dab558e4bd490cdffc487e640b9,
title = "Renal cell carcinoma: Molecular features and treatment updates",
abstract = "This book provides a comprehensive review of diagnosis and treatments of renal cell carcinoma (RCC) for practitioners and researchers with an interest in this disease. A major aim of the book is to present the most important and most recent advances in molecular bases and targeted therapy for this neoplasm. The remarkable resistance to chemotherapy and radiotherapy and the minimum contribution of cancer genes that commonly mutate in other adult epithelial cancers have made RCC highly distinct from other types of solid neoplasms. In the past decade, however, treatment options for RCC have been expanding and moving quickly toward laboratory-based and molecular-targeted therapies. Advances in RCC therapy also have brought novel treatment options to other types of cancer, such as a TKI for hepatocellular carcinoma and gastrointestinal tumors, as well as mTOR inhibitors to progressive neuroendocrine tumors of pancreatic origin and to breast cancer, suggesting that RCC is no longer an {"}orphan disease{"} in the field of molecular oncology. Additional topics covered in the book include pharmacokinetics and pharmacodynamics in molecular-targeted agents and the putative mechanism of resistance to anti-angiogenic agents, such as intratumoral heterogeneity or cancer stem cell population. This volume provides the latest and most useful information for all readers who are eagerly devoted to curing renal cell carcinoma.",
author = "Mototsugu Oya",
year = "2017",
month = "1",
day = "1",
doi = "10.1007/978-4-431-55531-5",
language = "English",
isbn = "9784431555308",
publisher = "Springer Japan",

}

TY - BOOK

T1 - Renal cell carcinoma

T2 - Molecular features and treatment updates

AU - Oya, Mototsugu

PY - 2017/1/1

Y1 - 2017/1/1

N2 - This book provides a comprehensive review of diagnosis and treatments of renal cell carcinoma (RCC) for practitioners and researchers with an interest in this disease. A major aim of the book is to present the most important and most recent advances in molecular bases and targeted therapy for this neoplasm. The remarkable resistance to chemotherapy and radiotherapy and the minimum contribution of cancer genes that commonly mutate in other adult epithelial cancers have made RCC highly distinct from other types of solid neoplasms. In the past decade, however, treatment options for RCC have been expanding and moving quickly toward laboratory-based and molecular-targeted therapies. Advances in RCC therapy also have brought novel treatment options to other types of cancer, such as a TKI for hepatocellular carcinoma and gastrointestinal tumors, as well as mTOR inhibitors to progressive neuroendocrine tumors of pancreatic origin and to breast cancer, suggesting that RCC is no longer an "orphan disease" in the field of molecular oncology. Additional topics covered in the book include pharmacokinetics and pharmacodynamics in molecular-targeted agents and the putative mechanism of resistance to anti-angiogenic agents, such as intratumoral heterogeneity or cancer stem cell population. This volume provides the latest and most useful information for all readers who are eagerly devoted to curing renal cell carcinoma.

AB - This book provides a comprehensive review of diagnosis and treatments of renal cell carcinoma (RCC) for practitioners and researchers with an interest in this disease. A major aim of the book is to present the most important and most recent advances in molecular bases and targeted therapy for this neoplasm. The remarkable resistance to chemotherapy and radiotherapy and the minimum contribution of cancer genes that commonly mutate in other adult epithelial cancers have made RCC highly distinct from other types of solid neoplasms. In the past decade, however, treatment options for RCC have been expanding and moving quickly toward laboratory-based and molecular-targeted therapies. Advances in RCC therapy also have brought novel treatment options to other types of cancer, such as a TKI for hepatocellular carcinoma and gastrointestinal tumors, as well as mTOR inhibitors to progressive neuroendocrine tumors of pancreatic origin and to breast cancer, suggesting that RCC is no longer an "orphan disease" in the field of molecular oncology. Additional topics covered in the book include pharmacokinetics and pharmacodynamics in molecular-targeted agents and the putative mechanism of resistance to anti-angiogenic agents, such as intratumoral heterogeneity or cancer stem cell population. This volume provides the latest and most useful information for all readers who are eagerly devoted to curing renal cell carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=85019493056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019493056&partnerID=8YFLogxK

U2 - 10.1007/978-4-431-55531-5

DO - 10.1007/978-4-431-55531-5

M3 - Book

SN - 9784431555308

BT - Renal cell carcinoma

PB - Springer Japan

ER -